7 results
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
characteristic features Clinical ... Treatment: Active ... Initiating Treatment ... TB #Diagnosis #Management ... #Treatment #ActiveTB
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
characteristic features Clinical ... Treatment: Active ... Initiating Treatment ... TB #Diagnosis #Management ... #Treatment #ActiveTB
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
IDSA - Clinical ... Individualized Treatment ... Multi-Drug Resistant Tuberculosis ... children with TB disease ... #MDRTB #management
Peripartum Cardiomyopathy - Summary
1. Definition
 • Towards the end of pregnancy to 5 months postpartum
Valvular heart disease ... cardiomyopathy • Pulmonary ... Clinical • Under-recognized ... teratogenic GDMT meds ... #cardiology #treatment
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... Mycobacterium Tuberculosis ... HIV-infected persons with clinical ... #TB #IDSA #Prevention ... #Treatment #management
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
Infection (Diffuse Pulmonary ... Extrathoracic Disseminated Disease ... • Use until clinical ... #Prevention #Treatment ... #management #opportunistic
Cryptogenic Organizing Pneumonia - Illness Script

PATHOPHYSIOLOGY: Unknown trigger, reversible inflammatory/fibroproliferative process. Polypoid fibroblastic aggregates that plug
DIAGNOSTICS: Clinical ... , neoplastic) TREATMENT ... steroids for severe disease ... Pneumonia #diagnosis #management ... #pulmonary